The impact of poor metabolic health on aggressive breast cancer: adipose tissue and tumor metabolism

被引:4
作者
Sankofi, Barbara Mensah [1 ]
Valencia-Rincon, Estefania [1 ]
Sekhri, Malika [1 ]
Ponton-Almodovar, Adriana L. [2 ,3 ,4 ]
Bernard, Jamie J. [2 ,3 ,4 ]
Wellberg, Elizabeth A. [1 ]
机构
[1] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA
[2] Michigan State Univ, Dept Pharmacol & Toxicol, E Lansing, MI USA
[3] Michigan State Univ, Nicolas V Perricone Div Dermatol, E Lansing, MI USA
[4] Michigan State Univ, Dept Med, E Lansing, MI USA
来源
FRONTIERS IN ENDOCRINOLOGY | 2023年 / 14卷
关键词
breast cancer; adipose; fibroblast growth factor; obesity; diabetes; BODY-MASS INDEX; GROWTH-FACTOR RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITION; SELECTIVE AROMATASE INHIBITOR; ESTROGEN-RECEPTOR; DIABETES-MELLITUS; ENDOCRINE THERAPY; MOLECULAR PORTRAITS; MEGESTROL-ACETATE; RISK-FACTOR;
D O I
10.3389/fendo.2023.1217875
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Obesity and type 2 diabetes are chronic metabolic diseases that impact tens to hundreds of millions of adults, especially in developed countries. Each condition is associated with an elevated risk of breast cancer and with a poor prognosis after treatment. The mechanisms connecting poor metabolic health to breast cancer are numerous and include hyperinsulinemia, inflammation, excess nutrient availability, and adipose tissue dysfunction. Here, we focus on adipose tissue, highlighting important roles for both adipocytes and fibroblasts in breast cancer progression. One potentially important mediator of adipose tissue effects on breast cancer is the fibroblast growth factor receptor (FGFR) signaling network. Among the many roles of FGFR signaling, we postulate that key mechanisms driving aggressive breast cancer include epithelial-to-mesenchymal transition and cellular metabolic reprogramming. We also pose existing questions that may help better understand breast cancer biology in people with obesity, type 2 diabetes, and poor metabolic health.
引用
收藏
页数:13
相关论文
共 166 条
  • [1] FGF10: Type III Epithelial Mesenchymal Transition and Invasion in Breast Cancer Cell Lines
    Abolhassani, Ali
    Riazi, Gholam Hossein
    Azizi, Ebrahim
    Amanpour, Saeid
    Muhammadnejad, Samad
    Haddadi, Mahnaz
    Zekri, Ali
    Shirkoohi, Reza
    [J]. JOURNAL OF CANCER, 2014, 5 (07): : 537 - 547
  • [2] FGFR-2 and Epithelial-Mesenchymal Transition in Endometrial Cancer
    Adamczyk-Gruszka, Olga
    Horecka-Lewitowicz, Agata
    Gruszka, Jakub
    Wawszczak-Kasza, Monika
    Strzelecka, Agnieszka
    Lewitowicz, Piotr
    [J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (18)
  • [3] Overcoming endocrine resistance in hormone receptor-positive breast cancer
    AlFakeeh, A.
    Brezden-Masley, C.
    [J]. CURRENT ONCOLOGY, 2018, 25 : S18 - S27
  • [4] Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model
    Alikhani, N.
    Ferguson, R. D.
    Novosyadlyy, R.
    Gallagher, E. J.
    Scheinman, E. J.
    Yakar, S.
    LeRoith, D.
    [J]. ONCOGENE, 2013, 32 (08) : 961 - 967
  • [5] From Krebs to clinic: glutamine metabolism to cancer therapy
    Altman, Brian J.
    Stine, Zachary E.
    Dang, Chi V.
    [J]. NATURE REVIEWS CANCER, 2016, 16 (10) : 619 - 634
  • [6] Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer
    Anbalagan, Muralidharan
    Rowan, Brian G.
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2015, 418 : 264 - 272
  • [7] [Anonymous], 2020, American Cancer Society. Cancer Facts Figures 2020
  • [8] Anurag Meenakshi, 2018, Oncotarget, V9, P36252, DOI 10.18632/oncotarget.26363
  • [9] Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers
    Anurag, Meenakshi
    Punturi, Nindo
    Hoog, Jeremy
    Bainbridge, Matthew N.
    Ellis, Matthew J.
    Haricharan, Svasti
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (19) : 4887 - 4899
  • [10] Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
    Bai, Xupeng
    Ni, Jie
    Beretov, Julia
    Graham, Peter
    Li, Yong
    [J]. CANCER LETTERS, 2021, 497 : 100 - 111